# A Multi-site Study of Autologous Cord Blood Cells for Hypoxic Ischemic Encephalopathy

> **NCT02612155** · PHASE2 · COMPLETED · sponsor: **Michael Cotten** · enrollment: 35 (actual)

## Conditions studied

- Moderate or Severe Hypoxic-ischemic Encephalopathy in Newborns

## Interventions

- **BIOLOGICAL:** Infusion of autologous cord blood
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT02612155
- **Lead sponsor:** Michael Cotten
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-03-30
- **Primary completion:** 2019-08-05
- **Final completion:** 2019-08-05
- **Target enrollment:** 35 (ACTUAL)
- **Last updated:** 2024-05-16

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02612155

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02612155, "A Multi-site Study of Autologous Cord Blood Cells for Hypoxic Ischemic Encephalopathy". Retrieved via AI Analytics 2026-06-04 from https://api.ai-analytics.org/clinical/NCT02612155. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*